1. Home
  2. SACH vs CELU Comparison

SACH vs CELU Comparison

Compare SACH & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.12

Market Cap

48.6M

Sector

Real Estate

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.96

Market Cap

56.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
CELU
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.6M
56.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SACH
CELU
Price
$1.12
$1.96
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$2.00
$6.00
AVG Volume (30 Days)
168.7K
65.1K
Earning Date
11-05-2025
11-14-2025
Dividend Yield
18.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,906,000.00
$40,578,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.73
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.00
52 Week High
$1.48
$4.35

Technical Indicators

Market Signals
Indicator
SACH
CELU
Relative Strength Index (RSI) 57.96 55.41
Support Level $1.00 $1.62
Resistance Level $1.08 $2.18
Average True Range (ATR) 0.05 0.14
MACD 0.01 0.04
Stochastic Oscillator 72.22 60.76

Price Performance

Historical Comparison
SACH
CELU

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: